Forbius
Forbius is a clinical-stage biopharmaceutical company founded in 2011 that develops biotherapeutics for the treatment of fibrotic diseases and cancers, headquartered in Austin, Texas.
- Company typePrivate
- Founded2011
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Forbius does
Forbius is a privately held, clinical-stage biopharmaceutical company founded in 2011 and headquartered in Austin, Texas. The company develops and designs biotherapeutics aimed at the treatment of fibrotic diseases and cancers, operating across two distinct therapeutic verticals that broaden its potential indication footprint. Its leadership team is oriented around research and development, comprising a Chief Scientific Officer, Chief Medical Officer, Chief Development Officer, and a Director of Preclinical Development, consistent with a company advancing candidates through preclinical and clinical stages rather than operating a commercial product franchise.
Forbius has funded its operations through a series of equity rounds and non-dilutive translational grants since 2012, drawing capital from healthcare-focused investors including HBM Partners, HBM Healthcare Investments, Lumira Ventures, and Rosseau Asset Management, alongside translational funders such as the Cancer Prevention and Research Institute of Texas and BioCanRx. The largest single disclosed capital event was an $18.8 million award from CPRIT in August 2018. The company has not disclosed any marketed product, pricing model, partnership economics, or revenue, and its public-facing website is limited to a contact form and an email signup, with no pipeline detail publicly available.
The company's revenue model is not yet defined commercially; as a pre-revenue developer, economics will ultimately depend on licensing, partnership, or royalty structures once any candidate reaches a commercial milestone. End customers, if and when products reach market, would be healthcare providers and payers rather than direct enterprise buyers, and customer concentration risk for any future revenue cannot be assessed from current evidence.
Forbius firmographics
Firmographics- Name
- Forbius
- Legal name
- Forbius
- Website
- https://forbius.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Forbius is a clinical-stage biopharmaceutical company founded in 2011 that develops biotherapeutics for the treatment of fibrotic diseases and cancers, headquartered in Austin, Texas.
- Ownership category
- akta.pro rank
Forbius industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Forbius is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Markets served
Forbius business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Distribution channels1 record
Marketing channels1 record
Forbius product offering
Product offeringCore offering
Forbius is a clinical-stage biopharmaceutical company that designs and develops biotherapeutics for the treatment of fibrotic diseases and cancers. The company operates a focused R&D organization advancing biologic drug candidates through preclinical and early clinical development, with the intent to bring targeted protein-based medicines to patients in high-unmet-need indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotherapeutic pipeline for fibrotic diseases Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of fibrotic diseases; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving patients with fibrosis.
- Biotherapeutic pipeline for cancers Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of cancers; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving oncology patients.
Companies that use Forbius
Customer profileIdeal customer profiles1 record
Forbius technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Forbius partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Forbius competitors and assessment
Company assessmentEmerging players
- BridgeBio Pharma: Clinical-stage biotech with fibrosis programs (e.g., BBP-418 for LGMD, infigratinib for achondroplasia). BridgeBio is comparable via its fibrosis franchise, though it operates at a much larger scale.
Broad incumbents
- Roche: Global biopharma with deep biologic oncology and fibrosis capabilities. Roche is a natural strategic acquirer for any specialized biologic platform in fibrosis or oncology.
- United Therapeutics: Commercial-stage biopharma with pulmonary fibrosis and pulmonary hypertension franchises. United Therapeutics is a relevant incumbent reference point for fibrosis drug development and commercial dynamics.
- Boehringer Ingelheim: Large pharma with a leading idiopathic pulmonary fibrosis franchise (nintedanib). Boehringer is a relevant incumbent that defines the competitive standard Forbius's fibrosis programs must beat.
- Bristol-Myers Squibb: Global biopharma with active fibrosis and oncology biologics portfolios. BMS is a relevant acquirer profile for specialty biologics in fibrosis/cancer, comparable in therapeutic focus if not in scale.
Direct peers
- Galapagos NV: Clinical-stage biotech with significant fibrosis and inflammation programs, including partnerships with larger pharma. Galapagos is comparable to Forbius on fibrosis indication and biologic modality.
- Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapeutics for fibrotic diseases. Pliant is directly comparable to Forbius in therapeutic area (fibrosis), modality (biologics), and corporate stage (clinical).
- Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibrosis and autoimmune disease. Morphic overlaps with Forbius on fibrosis biology, though its small-molecule approach differs in modality.
- Scholar Rock: Clinical-stage biotech developing biologics that target TGF-beta activation, with a focus on fibrosis and oncology. Scholar Rock is the closest mechanistic peer to Forbius's TGF-beta biology work and shares the same fibrosis/cancer therapeutic positioning.
- FibroGen: Late-stage biopharma developing therapeutics for fibrosis and anemia. FibroGen directly overlaps Forbius on fibrosis indication and biologic modality, and serves as a useful scale-up reference.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Forbius social profiles
Digital presenceForbius financial estimates
Financial estimateRevenue estimate
Valuation estimate
Forbius leadership team
Management profileNumber of profiles
Profiles4 records
Forbius funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Forbius M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Forbius
What does Forbius do?
Forbius is a clinical-stage biopharmaceutical company that designs and develops biotherapeutics for the treatment of fibrotic diseases and cancers. The company operates a focused R&D organization advancing biologic drug candidates through preclinical and early clinical development, with the intent to bring targeted protein-based medicines to patients in high-unmet-need indications.
When was Forbius founded?
Forbius was founded in 2011. It employs 11 to 50 people.
Where is Forbius based?
Forbius is headquartered in Austin, United States, in the North America region.
Who are Forbius's main competitors?
BridgeBio Pharma is listed as an emerging player. Broad incumbents are Roche, United Therapeutics, Boehringer Ingelheim and Bristol-Myers Squibb. Direct peers are Galapagos NV, Pliant Therapeutics, Morphic Holding, Scholar Rock and FibroGen.
Does Forbius have an API?
No public API is recorded for Forbius.
What industry is Forbius in?
Forbius's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2836.